Alutard SQ Bee Venom
Allergen immunotherapy for bee sting allergy (Apis mellifera venom extract)
Alutard SQ Bee Venom is a prescription allergen immunotherapy containing standardized honeybee venom extract (Apis mellifera). It is used as preventive treatment for patients who experience severe allergic reactions to bee stings. Administered as subcutaneous injections over 3 to 5 years, this treatment modifies the immune response to build lasting tolerance against bee venom, providing significant protection against life-threatening anaphylaxis.
Quick Facts
Key Takeaways
- Alutard SQ Bee Venom is a subcutaneous immunotherapy that treats the underlying cause of bee sting allergy by gradually building immune tolerance to honeybee venom.
- Treatment involves an updosing phase (7–25 weeks of weekly injections) followed by a maintenance phase (injections every 6–8 weeks for 3–5 years).
- Patients must remain under medical observation for at least 30 minutes after each injection due to the risk of anaphylaxis.
- Beta-blockers, ACE inhibitors, and certain antidepressants may increase the risk of severe allergic reactions and should be discussed with your physician.
- Venom immunotherapy provides approximately 77–95% protection against severe systemic reactions to bee stings, with the protective effect persisting for years after treatment completion.
What Is Alutard SQ Bee Venom and What Is It Used For?
Quick Answer: Alutard SQ Bee Venom is an allergen immunotherapy that contains a standardized extract of honeybee venom (Apis mellifera). It is prescribed as preventive treatment for patients with documented severe allergic reactions to bee stings, working by gradually reprogramming the immune system to tolerate bee venom.
Alutard SQ Bee Venom belongs to a class of treatments known as subcutaneous allergen immunotherapy (SCIT). Unlike medications that merely suppress allergic symptoms, this therapy addresses the fundamental immunological cause of bee venom allergy. The active ingredient is a purified, standardized allergen extract derived from the venom of the western honeybee (Apis mellifera), adsorbed onto aluminium hydroxide as an adjuvant.
The treatment is indicated for patients who have experienced severe systemic allergic reactions following a bee sting, including symptoms such as generalized urticaria (hives), angioedema (swelling of the face or throat), breathing difficulties, cardiovascular symptoms, or full anaphylaxis. According to the European Academy of Allergy and Clinical Immunology (EAACI), venom immunotherapy is strongly recommended for patients with a history of Grade III or IV systemic reactions and confirmed sensitization to bee venom by skin prick test or specific IgE measurement.
The mechanism of action involves gradually exposing the immune system to increasing amounts of bee venom allergen through regular subcutaneous injections. Over time, this shifts the immune response from a harmful IgE-mediated allergic pathway to a protective IgG4-mediated blocking pathway. The treatment also promotes the development of allergen-specific regulatory T cells, which further suppress the allergic inflammatory response. This immunological reprogramming results in long-term tolerance to bee venom, even after treatment discontinuation.
Alutard SQ Bee Venom is manufactured by ALK-Abelló A/S, a Danish pharmaceutical company that has been a pioneer in allergen immunotherapy since the 1920s. The product is approved and available across the European Economic Area (EEA) and the United Kingdom under various trade names, including Alutard SQ Bee in Belgium, Ireland, and the UK, and Alutard SQ Apis mellifera in Portugal, Spain, and Italy.
Alutard SQ Bee Venom is specifically for bee venom allergy. If you are allergic to wasp stings, a separate product containing wasp venom (Alutard SQ Wasp Venom) is required. Bee and wasp venoms contain different allergenic proteins, and cross-protection between the two is not reliable. Allergy testing can determine which specific venom you are sensitized to.
What Should You Know Before Taking Alutard SQ Bee Venom?
Quick Answer: Alutard SQ Bee Venom must not be used in patients with active uncontrolled asthma, severe immunodeficiency disorders, or severe cardiovascular disease. Several precautions apply, including pregnancy considerations and potential drug interactions. Always provide your physician with a complete medical history before starting treatment.
Contraindications
Alutard SQ Bee Venom should not be used if you have any of the following conditions:
- Hypersensitivity to excipients: Allergy to any of the inactive ingredients in the formulation, including aluminium hydroxide, sodium chloride, sodium bicarbonate, phenol, sodium hydroxide, or human albumin.
- Immunodeficiency disorders: Conditions that significantly impair immune system function, whether primary (inherited) or secondary (acquired, such as from immunosuppressive therapy), as the treatment relies on a functional immune response to achieve efficacy.
- Uncontrolled or severe asthma: A recent asthma exacerbation, worsening of asthma symptoms (increased daytime symptoms, nocturnal awakenings, increased rescue inhaler use, or limitation of physical activities) represents an absolute contraindication due to the significantly elevated risk of severe bronchospasm.
- Severe cardiovascular disease: Conditions such as unstable angina, recent myocardial infarction, severe heart failure, or uncontrolled arrhythmias, as these increase the risk of fatal outcomes in the event of anaphylaxis.
Warnings and Precautions
Inform your physician before receiving Alutard SQ Bee Venom if any of the following apply to you:
- Previous adverse reactions: If you experienced any side effects after a previous injection with Alutard SQ Bee Venom, your physician may need to adjust the dosage or administer premedication.
- Chronic heart disease: While not an absolute contraindication, chronic cardiac conditions require careful risk-benefit assessment and enhanced monitoring during treatment.
- Impaired kidney function: Because Alutard SQ contains aluminium hydroxide as an adjuvant, patients with reduced kidney function face a risk of aluminium accumulation in the body over the course of the multi-year treatment.
- Autoimmune conditions: Diseases such as rheumatoid arthritis, systemic lupus erythematosus, or multiple sclerosis may be exacerbated by immune stimulation, warranting careful evaluation.
- Cancer: Active malignancies may contraindicate immunotherapy due to the unpredictable effects of immune modulation on tumour behaviour.
- Fever or infection: Active infections or fever on the day of a scheduled injection may necessitate postponement, as the immune system is already activated and the risk of adverse reactions is increased.
- Recent allergic symptoms: If you have experienced allergic symptoms such as hay fever within the preceding 3 to 4 days, dose adjustments may be necessary.
- Worsening eczema: Active eczema flares may indicate heightened immune reactivity and warrant dose modification.
- Elevated tryptase levels or mastocytosis: Patients with elevated baseline serum tryptase or mastocytosis have a significantly increased risk of severe anaphylactic reactions during immunotherapy and require special protocols and possibly lifelong maintenance treatment.
- Asthma (controlled): Even well-controlled asthma increases the baseline risk of severe respiratory reactions. Pulmonary function should be assessed before each injection.
Severe allergic reactions, including anaphylaxis, can occur after any injection of Alutard SQ Bee Venom. Treatment must always be administered in a medical facility equipped with emergency resuscitation equipment. Patients must remain under observation for at least 30 minutes after each injection. On the day of injection, avoid strenuous physical exercise, hot baths, and alcohol consumption.
Children and Adolescents
Alutard SQ Bee Venom can be used in children aged 5 years and older, though clinical efficacy data in paediatric populations are limited. Safety data have not shown a higher risk in children compared to adults. For each child, the treating physician should carefully evaluate the individual risk-benefit ratio, taking into account the severity of previous reactions and the likelihood of future bee sting exposure.
For children under 5 years of age, the physician must exercise particular caution in weighing the risks of treatment against the potential benefits. Very young children may have difficulty communicating early symptoms of adverse reactions, which adds complexity to the safety monitoring process.
Pregnancy and Breastfeeding
The updosing phase of Alutard SQ Bee Venom should not be initiated during pregnancy due to the higher risk of systemic reactions during the dose-escalation period. If pregnancy occurs during an established maintenance regimen, the treating physician should evaluate whether to continue treatment, considering the individual risk of severe bee sting reactions against the potential risks of allergen immunotherapy during pregnancy.
It is not known whether Alutard SQ Bee Venom passes into breast milk. Women who are breastfeeding should discuss the risks and benefits with their physician before starting or continuing treatment. The EAACI guidelines suggest that ongoing maintenance immunotherapy may be continued during breastfeeding when the clinical benefit outweighs theoretical risks.
Driving and Operating Machinery
Alutard SQ Bee Venom may cause dizziness in some patients following an injection. If you experience dizziness or other symptoms that impair alertness, you should not drive or operate heavy machinery until the effects have resolved. It is prudent to arrange transportation from the clinic on injection days, particularly during the initial updosing phase when systemic reactions are more likely.
How Does Alutard SQ Bee Venom Interact with Other Drugs?
Quick Answer: Several drug classes can interact with Alutard SQ Bee Venom by either increasing the risk of severe allergic reactions or interfering with emergency treatment. The most clinically significant interactions involve beta-blockers, ACE inhibitors, tricyclic antidepressants, MAO inhibitors, and COMT inhibitors. Aluminum-containing medications may also pose cumulative toxicity concerns.
Drug interactions with allergen immunotherapy are particularly important because they can affect both the likelihood and treatability of anaphylaxis. Some medications increase the risk of severe allergic reactions, while others may impair the effectiveness of emergency epinephrine (adrenaline) if anaphylaxis occurs. Always inform your physician and pharmacist about all medications you are taking, including prescription drugs, over-the-counter products, and herbal supplements.
Major Interactions
| Drug Class | Examples | Interaction Mechanism | Clinical Significance |
|---|---|---|---|
| Beta-blockers | Atenolol, metoprolol, propranolol, bisoprolol | May increase severity of anaphylaxis and reduce effectiveness of epinephrine rescue treatment | High – physician must evaluate risk-benefit |
| ACE inhibitors | Enalapril, ramipril, lisinopril, perindopril | May increase risk of anaphylaxis by inhibiting bradykinin degradation, potentially worsening hypotension | High – consider alternative antihypertensive |
| Tricyclic antidepressants | Amitriptyline, nortriptyline, clomipramine | May potentiate cardiovascular effects of epinephrine, complicating anaphylaxis management | Moderate to high – monitor closely |
| MAO inhibitors | Phenelzine, tranylcypromine, moclobemide | May potentiate effects of catecholamines, altering the response to both anaphylaxis and its treatment | High – discuss with prescribing physician |
| COMT inhibitors | Entacapone, tolcapone (used in Parkinson’s disease) | May affect catecholamine metabolism, altering response to anaphylaxis treatment | Moderate – inform treating physician |
Minor Interactions and Considerations
| Drug Class | Examples | Interaction Detail | Recommendation |
|---|---|---|---|
| Antihistamines | Cetirizine, loratadine, fexofenadine | May mask early allergic symptoms and increase tolerance; physician may need to adjust immunotherapy dose | Inform physician; dose adjustments may be needed |
| Corticosteroids | Prednisolone, budesonide, methylprednisolone | Systemic corticosteroids may suppress the immune response that immunotherapy depends on for efficacy | Discuss with physician; may affect treatment outcome |
| Aluminium-containing antacids | Aluminium hydroxide, magaldrate | Alutard SQ contains aluminium adjuvant; concurrent aluminium intake may increase risk of accumulation, especially in patients with renal impairment | Use cautiously; monitor renal function |
| Vaccines | Tetanus, influenza, COVID-19 vaccines | Concurrent immune stimulation may increase risk of adverse reactions | Allow at least 1 week between immunotherapy injection and vaccination |
Alcohol consumption should be avoided on the day of injection, as it can increase the risk of severe allergic reactions (anaphylaxis) by promoting vasodilation and impairing the body's ability to mount an appropriate compensatory cardiovascular response.
What Is the Correct Dosage of Alutard SQ Bee Venom?
Quick Answer: Alutard SQ Bee Venom treatment is divided into two phases: an updosing phase lasting 7 to 25 weeks with gradually increasing doses given approximately weekly, followed by a maintenance phase with injections every 6 to 8 weeks for 3 to 5 years. All injections are administered subcutaneously by a trained healthcare professional.
Alutard SQ Bee Venom is an injection-based treatment that must be administered by a physician or trained nurse in a clinical setting. The medication is never self-administered. The treatment follows a carefully structured dosing protocol designed to safely build immune tolerance while minimizing the risk of adverse reactions.
Updosing Phase
The updosing (dose-escalation) phase is the initial period of treatment during which the allergen dose is gradually increased to reach the target maintenance level. This phase typically takes between 7 and 25 weeks, depending on the specific dosing schedule chosen by the prescribing physician. Standard protocols involve one injection per week.
The product is supplied in four vials of increasing strength, each identified by a colour-coded cap:
| Vial Number | Colour Code | Strength | Aluminium Content |
|---|---|---|---|
| Vial 1 | Grey | 100 SQ-E/ml | 0.00113 mg/ml |
| Vial 2 | Green | 1,000 SQ-E/ml | 0.0113 mg/ml |
| Vial 3 | Orange | 10,000 SQ-E/ml | 0.113 mg/ml |
| Vial 4 | Red | 100,000 SQ-E/ml | 1.13 mg/ml |
During updosing, the physician begins with the lowest strength vial and gradually increases both the volume and vial strength according to a predefined schedule. If a local reaction at the injection site persists for more than six hours, the physician will adjust the subsequent dose based on the size of the skin reaction. Premedication with an antihistamine may be administered before the injection to improve tolerance.
Maintenance Phase
Once the maximum tolerated dose or the recommended maintenance dose (typically 1.0 ml of the 100,000 SQ-E/ml vial) has been reached, the interval between injections is gradually extended. During the maintenance phase, injections are given every 6 to 8 weeks. This phase continues for 3 to 5 years, as recommended by the EAACI guidelines, to achieve lasting immunological tolerance.
The maintenance dose represents the therapeutic level at which the immune system receives sufficient allergen exposure to sustain the protective immunological changes. Consistent adherence to the maintenance schedule is essential for treatment success. Research published in the Journal of Allergy and Clinical Immunology has demonstrated that patients who complete the full 3 to 5 year course of venom immunotherapy maintain protection for at least 7 to 10 years after discontinuation.
Children
The dosing schedule for children aged 5 years and older generally follows the same protocol as for adults. However, the treating physician may modify the updosing speed or target maintenance dose based on the individual child's tolerance, body weight, and clinical response. Close monitoring is essential, as young children may have difficulty reporting early symptoms of adverse reactions.
Elderly Patients
No specific dose adjustments are recommended solely based on age. However, elderly patients are more likely to have cardiovascular comorbidities and renal impairment, which may influence both the risk profile of treatment and the choice of concomitant medications. The treating physician should carefully evaluate cardiac function and kidney function before initiating therapy in this population.
Missed Dose
If the interval between scheduled injections exceeds the recommended timeframe, the physician will reduce the dose for the next injection to decrease the risk of an allergic reaction. The extent of the dose reduction depends on how long the treatment was interrupted. Inform your physician if you believe you have missed a scheduled injection so that the dosing can be safely readjusted.
Overdose
Since Alutard SQ Bee Venom is exclusively administered by healthcare professionals in a clinical setting, overdose is uncommon. In the event that an excessive dose is inadvertently administered, the patient will be closely monitored and treated for any allergic reactions that may occur. Symptoms of overdose would be consistent with an acute allergic reaction or anaphylaxis and would be managed with standard emergency protocols including epinephrine, antihistamines, and corticosteroids.
If you are receiving immunotherapy with more than one allergen simultaneously (for example, both bee venom and wasp venom), the injections should be given at least 30 minutes apart to allow accurate identification of the causative allergen in the event of a systemic reaction.
What Are the Side Effects of Alutard SQ Bee Venom?
Quick Answer: The most frequently reported side effects of Alutard SQ Bee Venom are local injection site reactions, including swelling, redness, itching, and pain. Systemic reactions such as headache, dizziness, and fatigue can also occur. Severe anaphylactic reactions are rare but possible, which is why every injection must be administered under medical supervision with at least 30 minutes of post-injection observation.
Like all medicines, Alutard SQ Bee Venom can cause side effects, although not everyone experiences them. The side effects are a consequence of the immune system's response to the administered allergen. Local reactions at the injection site are expected and generally indicate that the immune system is responding to the treatment. Most side effects appear within 30 minutes of the injection, though delayed reactions may occur up to 24 hours later.
Injection Site Reactions
Very common – expected after most injections
- Swelling at the injection site
- Redness (erythema)
- Itching (pruritus)
- Pain or tenderness
- Nodules or lumps at the injection site
- Localised hair growth at injection site
Common Systemic Side Effects
Reported in a notable proportion of patients
- Headache
- Dizziness
- Fatigue and general malaise
- Skin rash
- Sensation of warmth
- Tingling sensation in the skin (paraesthesia)
Uncommon Side Effects
Reported less frequently
- Swollen eyelids
- Eye inflammation or itching
- Heart palpitations or irregular heartbeat
- Low blood pressure (hypotension)
- Nasal congestion
- Wheezing or cough
- Joint pain or swelling
- Tissue swelling (typically lower extremities)
- Chest discomfort
- Feeling of a foreign body in the throat
Rare but Serious – Seek Immediate Medical Help
Rare – require immediate emergency treatment
- Anaphylaxis (sudden onset of facial/throat swelling, difficulty swallowing, breathing difficulties)
- Generalised urticaria (hives spreading over the body)
- Sudden skin flushing
- Severe bronchospasm or worsening of asthma
- Pallor (paleness indicating circulatory compromise)
- Severe nausea, abdominal pain, vomiting, and diarrhoea
- Cardiovascular collapse
Seek immediate medical attention if you experience any of the following symptoms after an injection: sudden swelling of the face or throat, difficulty breathing or swallowing, widespread hives, rapid heartbeat, severe dizziness, or a sudden feeling of faintness. These symptoms may indicate anaphylaxis, a life-threatening allergic reaction that requires emergency treatment with epinephrine. If your asthma suddenly worsens after an injection, alert the medical staff immediately.
The risk of systemic reactions is generally highest during the updosing phase when allergen doses are being increased. Once the maintenance dose is established, serious reactions become less frequent. According to a systematic review in the Cochrane Database of Systematic Reviews, the overall rate of systemic reactions during venom immunotherapy is approximately 14–20%, with severe life-threatening reactions occurring in less than 2% of patients. The vast majority of these reactions can be successfully managed with prompt medical intervention.
Local reactions at the injection site typically resolve within hours to days and do not usually require treatment discontinuation. Applying a cold compress to the injection site may help relieve swelling and discomfort. If local reactions become excessive (greater than the size of a fist or persisting for more than 24 hours), inform your physician so the dosing schedule can be adjusted.
How Should You Store Alutard SQ Bee Venom?
Quick Answer: Alutard SQ Bee Venom must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). It must not be frozen. Keep in the original packaging to protect from light. Once opened, the vial is stable for 6 months when stored correctly in the refrigerator and used for a single patient.
Proper storage is essential to maintain the potency and safety of Alutard SQ Bee Venom. The product must be stored under refrigerated conditions at all times, as exposure to elevated temperatures or freezing can degrade the allergen extract and potentially alter its immunogenic properties, leading to unpredictable clinical effects.
- Temperature: Store at 2°C to 8°C (36°F to 46°F) in a refrigerator. Do not freeze. Freezing may damage the aluminium hydroxide adjuvant structure and alter the allergen release profile.
- Light protection: Keep in the original carton to protect the suspension from light, which can degrade the protein allergens.
- After opening: Once a vial is first punctured, it remains usable for 6 months when stored in the refrigerator and used for a single patient only.
- Expiry date: Do not use after the expiry date printed on the label (EXP). The expiry date refers to the last day of the stated month.
- Keep out of reach of children: Store this medicine where children cannot see or reach it.
Before each use, the vial should be slowly inverted 10 to 20 times to ensure a homogeneous suspension. A sedimented layer with clear supernatant is normal and does not indicate product deterioration. The resuspended product should appear white to slightly brownish or greenish. Do not use if visible particles are observed after resuspension. Dispose of unused medicine in accordance with local regulations; do not pour it down the drain or place it in household waste.
What Does Alutard SQ Bee Venom Contain?
Quick Answer: The active ingredient is a standardized allergen extract from honeybee venom (Apis mellifera), adsorbed onto aluminium hydroxide. Inactive ingredients include sodium chloride, sodium bicarbonate, phenol (preservative), sodium hydroxide, human albumin solution, and water for injections.
Active Ingredient
The active substance is a purified, standardized allergen extract from the venom of the western honeybee (Apis mellifera). The potency is expressed in Standardized Quality units (SQ-E/ml), a proprietary bioassay-based unit developed by ALK-Abelló that accounts for both the allergen content and its biological activity. The allergen is adsorbed onto aluminium hydroxide (hydrated), which serves as an adjuvant to enhance and prolong the immune response.
Inactive Ingredients (Excipients)
- Aluminium hydroxide (hydrated): Adjuvant that creates a depot effect, allowing slow release of the allergen from the injection site
- Sodium chloride: Maintains isotonicity of the solution
- Sodium bicarbonate: pH buffering agent
- Phenol: Preservative to prevent microbial contamination
- Sodium hydroxide: pH adjustment
- Human albumin solution: Protein stabilizer that prevents allergen adsorption to container surfaces
- Water for injections: Solvent
Alutard SQ Bee Venom contains less than 1 mmol sodium (23 mg) per dose, making it essentially sodium-free. This is relevant for patients on sodium-restricted diets.
Appearance
Alutard SQ Bee Venom is a suspension for injection. The suspension appears white to slightly brownish or greenish in colour. During storage, sedimentation may occur with a clear layer of liquid above the settled particles – this is normal for a suspension and does not indicate loss of quality. The product is available in two pack types: a strength series containing four vials (one of each strength) for the updosing phase, and a single maintenance vial at 100,000 SQ-E/ml for the maintenance phase.
Frequently Asked Questions About Alutard SQ Bee Venom
Alutard SQ Bee Venom is an allergen immunotherapy used as preventive treatment for bee sting allergy. It is prescribed for patients who have experienced severe allergic reactions (anaphylaxis) following a bee sting. The treatment works by gradually building up the immune system's tolerance to honeybee venom over a period of 3 to 5 years, significantly reducing the risk of life-threatening reactions to future bee stings.
The complete treatment course typically lasts 3 to 5 years. The initial updosing phase takes 7 to 25 weeks, during which injections are given approximately once per week with progressively increasing doses. Once the maintenance dose is reached, injections are spaced out to every 6 to 8 weeks for the remaining treatment period. Research suggests that the protective effect can persist for 7 to 10 years or longer after completing the full course.
No. Alutard SQ Bee Venom must always be administered in a medical facility by a trained healthcare professional. After each injection, you must remain under medical observation for at least 30 minutes so that any allergic reaction can be promptly identified and treated. The clinic must have emergency resuscitation equipment and epinephrine readily available. Home self-administration of this product is not permitted.
On the day of your injection, you should avoid strenuous physical exercise, hot baths or saunas, and alcohol consumption. These activities can increase blood circulation and vasodilation, which may enhance allergen absorption and increase the risk of a severe allergic reaction. It is generally recommended to take it easy for the remainder of the injection day and resume normal activities the following day.
No. Alutard SQ Bee Venom is specifically formulated for bee venom (Apis mellifera) allergy and does not provide reliable protection against wasp sting allergy. Bee and wasp venoms contain different allergenic proteins that trigger distinct immune responses. If you are allergic to wasp stings, a separate product containing wasp venom (such as Alutard SQ Wasp Venom) would be needed. Allergy testing with skin prick tests or blood tests for specific IgE can determine which venom(s) you are sensitized to.
According to systematic reviews and the EAACI guidelines (2023), venom immunotherapy with standardized honeybee venom extracts provides approximately 77 to 84% protection against systemic reactions to bee stings. Some studies report even higher effectiveness (up to 95%) for wasp venom immunotherapy. The treatment is the only available therapy that addresses the underlying cause of venom allergy rather than merely managing symptoms. The protective effect typically persists for many years after completing the recommended 3 to 5 year treatment course.
References
This article is based on the following peer-reviewed sources and international clinical guidelines:
- European Medicines Agency (EMA). Alutard SQ – Summary of Product Characteristics. Available at: www.ema.europa.eu.
- Dhami S, Zaman H, Varga EM, et al. Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis. Allergy. 2017;72(3):342–365. doi:10.1111/all.13077
- Sturm GJ, Varga EM, Roberts G, et al. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy. 2018;73(4):744–764. doi:10.1111/all.13262
- Boyle RJ, Elremeli M, Hockenhull J, et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database of Systematic Reviews. 2012;(10):CD008838. doi:10.1002/14651858.CD008838.pub2
- Cardona V, Ansotegui IJ, Ebisawa M, et al. World Allergy Organization Anaphylaxis Guidance 2020. World Allergy Organization Journal. 2020;13(10):100472. doi:10.1016/j.waojou.2020.100472
- Golden DBK, Demain J, Freeman T, et al. Stinging insect hypersensitivity: a practice parameter update 2016. Annals of Allergy, Asthma & Immunology. 2017;118(1):28–54. doi:10.1016/j.anai.2016.10.031
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd list (2023). Geneva: WHO; 2023.
- Rueff F, Vos B, Oude Elberink J, et al. Predictors of clinical effectiveness of Hymenoptera venom immunotherapy. Clinical & Experimental Allergy. 2014;44(5):736–746. doi:10.1111/cea.12275
Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, a multidisciplinary group of licensed healthcare professionals with specialist expertise in allergy, immunology, pharmacology, and evidence-based medicine.
Licensed physicians and pharmacologists with clinical experience in allergology and immunotherapy, specializing in translating complex medical evidence into accessible patient information.
Board-certified allergists and immunologists who verify all clinical content against current international guidelines (EAACI, WAO, EMA) and the latest peer-reviewed literature.
Our editorial process follows the GRADE evidence framework, ensuring that all medical claims are supported by the highest available level of evidence. Content is independently produced with no pharmaceutical company sponsorship or advertising influence. For more information, visit our Editorial Standards page.